Summary of Presentations from the Sandoz Biopharmaceuticals-Sponsored Educational Session, which was part of the ‘Updates-in-Hematology’ Programme, held at the 19th EHA Congress, Milan, Italy, on 11th June 2014
Chairperson: Pier Luigi Zinzani1
Speakers: Joerg Windisch,2 Steffen Thirstrup,3 Wojciech Jurczak,4 Paul Cornes5
1. Institute of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy
2. Chief Science Officer, Sandoz Biopharmaceuticals, Kundl, Austria
3. Director, NDA Regulatory Advisory Board
4. Department of Hematology, Jagiellonian University, Krakow, Poland
5. Bristol Haematology and Oncology Centre and Bristol Royal Hospital for Children, Bristol, UK
Disclosure: Pier Luigi Zinzani has a financial interest/relationship or affiliation in the form of consultancy for Bayer AG and Sandoz and has participated in speaker bureaus for Celgene International Sàrl, MundiPharma International Ltd, Pfizer Inc., and Takeda Pharmaceutical Company Limited. Pier Luigi Zinzani has received honoraria from and served on scientific advisory boards (SABs) for Celgene International, Sàrl, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, MundiPharma International Ltd, and Takeda Pharmaceutical Company Ltd., and honoraria from Pfizer Inc. and SAB for Bayer AG and Gilead. Joerg Windisch is an employee of Sandoz Biopharmaceuticals. Steffen Thirstrup is a full-time employee at NDA Regulatory Services Ltd., which has a contractual agreement for his participation in this educational session. Wojciech Jurczak has received research funding from Celgene, Eisai, Gilead, Janssen, Pharmacyclics, Pfizer, Roche, Sandoz–Novartis, Spectrum, Takeda, and Teva, and has served on SABs for MundiPharma, Sandoz–Novartis, Spectrum, Takeda, and Teva. Paul Cornes has received salary from the UK NHS and honoraria from Roche, Janssen, Sandoz, Lilly, European Generics Association, Teva, and Hospira.
Acknowledgements: Writing assistance provided by Dr Tom Priddle, ApotheCom ScopeMedical.
Support: The publication of this article was funded by Sandoz Biopharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Sandoz Biopharmaceuticals.
Citation: EMJ Hema. 2014;1:30-39.